inPractice® - Dolutegravir vs Efavirenz in Treatment-Naive Patients

The double-blind phase III SINGLE study compared dolutegravir plus abacavir/lamivudine (n = 411) to efavirenz/emtricitabine/tenofovir (n = 419) in treatment-naive patients^{[Walmsley 2013]}
The dolutegravir regimen was superior to the efavirenz regimen at the Week 48 primary efficacy analysis with 88% vs 81%, respectively, achieving HIV-1 RNA < 50 copies/mL^{[Walmsley 2013]}
- Superior efficacy of the dolutegravir regimen was maintained at the Week 144 analysis with 71% vs 63%, respectively, achieving HIV-1 RNA < 50 copies/mL^{[Walmsley 2015]}